207 related articles for article (PubMed ID: 32890778)
1. Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits.
Thrailkill KM; Bunn RC; Uppuganti S; Ray P; Popescu I; Kalaitzoglou E; Fowlkes JL; Nyman JS
Bone; 2020 Dec; 141():115625. PubMed ID: 32890778
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.
Thrailkill KM; Clay Bunn R; Nyman JS; Rettiganti MR; Cockrell GE; Wahl EC; Uppuganti S; Lumpkin CK; Fowlkes JL
Bone; 2016 Jan; 82():101-7. PubMed ID: 26211996
[TBL] [Abstract][Full Text] [Related]
3. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.
Thrailkill KM; Nyman JS; Bunn RC; Uppuganti S; Thompson KL; Lumpkin CK; Kalaitzoglou E; Fowlkes JL
Bone; 2017 Jan; 94():141-151. PubMed ID: 27989651
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of canagliflozin treatment on the skeleton of aged UM-HET3 mice.
Yildirim G; Bergamo ETP; Poudel SB; Ruff RR; Dixit M; Hu B; Mijares DQ; Witek L; Chlebek C; Harrison DE; Strong R; Miller RA; Ladiges W; Bromage TG; Rosen CJ; Yakar S
Geroscience; 2023 Jun; 45(3):1933-1951. PubMed ID: 37166526
[TBL] [Abstract][Full Text] [Related]
5. Sex-dependent effects of Canagliflozin on kidney protection in mice with combined hypertension-type 1 diabetes.
Trentin-Sonoda M; Cheff V; Gutsol A; Hébert RL
PLoS One; 2023; 18(12):e0295284. PubMed ID: 38055691
[TBL] [Abstract][Full Text] [Related]
6. Low bone toughness in the TallyHO model of juvenile type 2 diabetes does not worsen with age.
Creecy A; Uppuganti S; Unal M; Clay Bunn R; Voziyan P; Nyman JS
Bone; 2018 May; 110():204-214. PubMed ID: 29438824
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
Woods TC; Satou R; Miyata K; Katsurada A; Dugas CM; Klingenberg NC; Fonseca VA; Navar LG
Am J Nephrol; 2019; 49(4):331-342. PubMed ID: 30921791
[TBL] [Abstract][Full Text] [Related]
8. Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone.
Thrailkill KM; Bunn RC; Uppuganti S; Ray P; Garrett K; Popescu I; Pennings JS; Fowlkes JL; Nyman JS
Bone; 2020 Apr; 133():115254. PubMed ID: 31991250
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and Skeletal Characterization of the KK/A
Chowdhury NN; Surowiec RK; Kohler RK; Reul ON; Segvich DM; Wallace JM
Calcif Tissue Int; 2024 Jun; 114(6):638-649. PubMed ID: 38642089
[TBL] [Abstract][Full Text] [Related]
10. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
Shao M; Chen D; Wang Q; Guo F; Wei F; Zhang W; Gan T; Luo Y; Fan X; Du P; Liu Y; Ma X; Ren G; Song Y; Zhao Y; Qin G
Diabetologia; 2024 Apr; 67(4):738-754. PubMed ID: 38236410
[TBL] [Abstract][Full Text] [Related]
11. Canagliflozin promotes osteoblastic MC3T3-E1 differentiation
Song P; Chen T; Rui S; Duan X; Deng B; Armstrong DG; Ma Y; Deng W
Front Endocrinol (Lausanne); 2022; 13():1081039. PubMed ID: 36589840
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin alleviates LPS-induced acute lung injury by modulating alveolar macrophage polarization.
Lin F; Song C; Zeng Y; Li Y; Li H; Liu B; Dai M; Pan P
Int Immunopharmacol; 2020 Nov; 88():106969. PubMed ID: 33182027
[TBL] [Abstract][Full Text] [Related]
13. Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus.
Koike Y; Shirabe SI; Maeda H; Yoshimoto A; Arai K; Kumakura A; Hirao K; Terauchi Y
Diabetes Res Clin Pract; 2019 Mar; 149():140-146. PubMed ID: 30716347
[TBL] [Abstract][Full Text] [Related]
14. Streptozotocin-Treated High Fat Fed Mice: A New Type 2 Diabetes Model Used to Study Canagliflozin-Induced Alterations in Lipids and Lipoproteins.
Yu T; Sungelo MJ; Goldberg IJ; Wang H; Eckel RH
Horm Metab Res; 2017 May; 49(5):400-406. PubMed ID: 28395380
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM-HET3 mice.
Jayarathne HSM; Debarba LK; Jaboro JJ; Ginsburg BC; Miller RA; Sadagurski M
Aging Cell; 2022 Jul; 21(7):e13653. PubMed ID: 35707855
[TBL] [Abstract][Full Text] [Related]
16. Changes in the Fracture Resistance of Bone with the Progression of Type 2 Diabetes in the ZDSD Rat.
Creecy A; Uppuganti S; Merkel AR; O'Neal D; Makowski AJ; Granke M; Voziyan P; Nyman JS
Calcif Tissue Int; 2016 Sep; 99(3):289-301. PubMed ID: 27209312
[TBL] [Abstract][Full Text] [Related]
17. Utility and Limitations of TALLYHO/JngJ as a Model for Type 2 Diabetes-Induced Bone Disease.
Emini L; Salbach-Hirsch J; Krug J; Jähn-Rickert K; Busse B; Rauner M; Hofbauer LC
JBMR Plus; 2023 Dec; 7(12):e10843. PubMed ID: 38130754
[TBL] [Abstract][Full Text] [Related]
18. Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway.
Huang S; Wu B; He Y; Qiu R; Yang T; Wang S; Lei Y; Li H; Zheng F
Hepatol Commun; 2023 Mar; 7(3):e0045. PubMed ID: 36757426
[TBL] [Abstract][Full Text] [Related]
19. Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.
Martinez R; Al-Jobori H; Ali AM; Adams J; Abdul-Ghani M; Triplitt C; DeFronzo RA; Cersosimo E
Diabetes; 2018 Jun; 67(6):1182-1189. PubMed ID: 29602791
[TBL] [Abstract][Full Text] [Related]
20. Canagliflozin impairs blood reperfusion of ischaemic lower limb partially by inhibiting the retention and paracrine function of bone marrow derived mesenchymal stem cells.
Lin Y; Nan J; Shen J; Lv X; Chen X; Lu X; Zhang C; Xiang P; Wang Z; Li Z
EBioMedicine; 2020 Feb; 52():102637. PubMed ID: 31981975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
